SEC Comment Letter for Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Dec 7, 2017
Aptose Biosciences Inc. (CIK 0000882361)
Date: Dec. 7, 2017 · CIK: 0000882361 · Accession: 0000000000-17-042819
AI Filing Summary & Sentiment
Letter
December 6, 2017 William G. Rice Chief Executive Officer Aptose Biosciences Inc. 5955 Airport Road, Suite 228 Mississauga, Ontario L4V 1R9 Canada Aptose Biosciences Inc. Registration Statement on Form F-1 Filed November 28, 2017 File No. 333-221783Re: Dear Dr. Rice: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Daniel M. Miller, Esq.
Show Raw Text
December 6, 2017
William G. Rice
Chief Executive Officer
Aptose Biosciences Inc.
5955 Airport Road, Suite 228
Mississauga, Ontario L4V 1R9
Canada
Aptose Biosciences Inc.
Registration Statement on Form F-1
Filed November 28, 2017
File No. 333-221783Re:
Dear Dr. Rice:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Daniel M. Miller, Esq.